Movatterモバイル変換


[0]ホーム

URL:


CA2444814A1 - Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures - Google Patents

Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
Download PDF

Info

Publication number
CA2444814A1
CA2444814A1CA002444814ACA2444814ACA2444814A1CA 2444814 A1CA2444814 A1CA 2444814A1CA 002444814 ACA002444814 ACA 002444814ACA 2444814 ACA2444814 ACA 2444814ACA 2444814 A1CA2444814 A1CA 2444814A1
Authority
CA
Canada
Prior art keywords
coating layer
poly
methacrylic acid
methyl methacrylate
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002444814A
Other languages
French (fr)
Other versions
CA2444814C (en
Inventor
Gregory Paul Dittmar
Joseph Michael Amante
Tony Ryan Cronk
Daniel Gary Newby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=29783760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2444814(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IndividualfiledCriticalIndividual
Priority claimed from CA002359812Aexternal-prioritypatent/CA2359812C/en
Publication of CA2444814A1publicationCriticalpatent/CA2444814A1/en
Application grantedgrantedCritical
Publication of CA2444814CpublicationCriticalpatent/CA2444814C/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by administering the above compositions to a human or lower animal.
CA002444814A2001-10-242001-10-24Pharmaceutical dosage form with multiple coatings for reduced impact of coating fracturesExpired - LifetimeCA2444814C (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CA002359812ACA2359812C (en)2000-11-202001-10-24Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
CA002359812ADivisionCA2359812C (en)2000-11-202001-10-24Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Publications (2)

Publication NumberPublication Date
CA2444814A1true CA2444814A1 (en)2002-05-20
CA2444814C CA2444814C (en)2009-06-09

Family

ID=29783760

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CA002444814AExpired - LifetimeCA2444814C (en)2001-10-242001-10-24Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Country Status (1)

CountryLink
CA (1)CA2444814C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9597293B2 (en)2007-05-072017-03-21Evonik Röhm GmbhSolid dosage forms comprising an enteric coating with accelerated drug release
EP3162362A1 (en)*2015-10-302017-05-03Dr. Falk Pharma GmbhOptimized high-dose tablet of mesalazine

Cited By (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9597293B2 (en)2007-05-072017-03-21Evonik Röhm GmbhSolid dosage forms comprising an enteric coating with accelerated drug release
EP2152250B1 (en)*2007-05-072019-09-04Evonik Röhm GmbHSolid dosage forms comprising an enteric coating with accelerated drug release
US10537530B2 (en)2007-05-072020-01-21Evonik Operations GmbhSolid dosage forms comprising an enteric coating with accelerated drug release
EP3162362A1 (en)*2015-10-302017-05-03Dr. Falk Pharma GmbhOptimized high-dose tablet of mesalazine
WO2017072050A1 (en)*2015-10-302017-05-04Dr. Falk Pharma GmbhOptimised high-dose mesalazine-containing tablet
US11135159B2 (en)2015-10-302021-10-05Dr. Falk Pharma GmbhOptimized high-dose mesalazine-containing tablet

Also Published As

Publication numberPublication date
CA2444814C (en)2009-06-09

Similar Documents

PublicationPublication DateTitle
CA2359812A1 (en)Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
IL161628A0 (en)Pharmaceutical dosage form with multiple coatings
KR100283709B1 (en) Stable Sustained Release Oral Dosage Composition
EP1275381A4 (en)Time-release coated solid compositions for oral administration
US6103266A (en)Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US5686094A (en)Controlled release formulations for the treatment of xerostomia
US5102666A (en)Calcium polycarbophil controlled release composition and method
WO2004108162A3 (en)Controlled release pharmaceutical composition
CA2277365A1 (en)Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO2006058249A3 (en)Methods and compositions for deterring abuse of orally administered pharmaceutical products
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
ES2611995T3 (en) Methods and compositions for the delivery of a therapeutic agent
JP2005515966A5 (en)
JP2006514058A (en) Rapid dissolution film for oral administration of drugs
RU2009110452A (en) GALENE COMPOSITIONS OF ALISKIREN
WO2004002445A3 (en)Novel floating dosage form
WO2002017855A3 (en)Process for preparing pharmaceutical compositions for use with soft gelatin formulations
CA2143413A1 (en)Local Drug Delivery Film, for Periodontal Treatment
HK1042303A1 (en)New compounds
EP0497956B1 (en)Controlled release formulations
CA2415957A1 (en)Dry powder formulation comprising racecadotril
US20200323834A1 (en)Hydrophobic acid addition salts and pharmaceutical formulations thereof
CA2444814A1 (en)Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2000066550A8 (en)New compounds
CA2472449A1 (en)Pharmaceutical composition for oral use with improved absorption

Legal Events

DateCodeTitleDescription
EEERExamination request
MKEXExpiry

Effective date:20211025


[8]ページ先頭

©2009-2025 Movatter.jp